TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation: Prospective, Multi-centre, Parallel-group, Non-inferiority Trial (RE-LY Study)
Brief Summary: The primary objective of this trial is to demonstrate the efficacy and safety of dabigatran etexilate in patients with non-valvular atrial fibrillation for the prevention of stroke and systemic embolism.


Options:
A: Arm Label: Dabigatran dose 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 2 | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: Dabigatran dose 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 1 | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Dabigatran dose 1; Assigned to Arm(s): Dabigatran dose 1 | Intervention Type: DRUG; Name: Dabigatran dose 2; Assigned to Arm(s): Dabigatran dose 2
B: Arm Label: Dabigatran etexilate (150mg bid); Type: EXPERIMENTAL; Interventions: Drug: Dabigatran etexilate | Arm Label: Warfarin (INR 2.0-3.0); Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin (INR 2.0-3.0) | Intervention Type: DRUG; Name: Dabigatran etexilate; Assigned to Arm(s): Dabigatran etexilate (150mg bid)
C: Arm Label: Dabigatran; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran | Arm Label: Warfarin (INR of 2.0-3.0); Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Dabigatran; Assigned to Arm(s): Dabigatran | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin (INR of 2.0-3.0)
D: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939), Drug: Warfarin placebo | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin, Drug: Rivaroxaban placebo | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Rivaroxaban placebo; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Warfarin placebo; Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation: Prospective, Multi-centre, Parallel-group, Non-inferiority Trial (RE-LY Study)
Brief Summary: The primary objective of this trial is to demonstrate the efficacy and safety of dabigatran etexilate in patients with non-valvular atrial fibrillation for the prevention of stroke and systemic embolism.


Options:
A: Arm Label: DU-176b 15 mg group; Type: EXPERIMENTAL; Interventions: Drug: Du-176b | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Du-176b; Assigned to Arm(s): DU-176b 15 mg group | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo group
B: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939), Other: Rivaroxaban-Placebo | Arm Label: Aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetylsalicylic acid (Aspirin, BAY1019036), Other: Aspirin-Placebo | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Acetylsalicylic acid (Aspirin, BAY1019036); Assigned to Arm(s): Aspirin | Intervention Type: OTHER; Name: Rivaroxaban-Placebo; Assigned to Arm(s): Rivaroxaban | Intervention Type: OTHER; Name: Aspirin-Placebo; Assigned to Arm(s): Aspirin
C: Arm Label: Dabigatran dose 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 2 | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: Dabigatran dose 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 1 | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Dabigatran dose 1; Assigned to Arm(s): Dabigatran dose 1 | Intervention Type: DRUG; Name: Dabigatran dose 2; Assigned to Arm(s): Dabigatran dose 2
D: Arm Label: Early start of NOAC; Type: ACTIVE_COMPARATOR; Interventions: Other: Early start of NOAC | Arm Label: Late start of NOAC; Type: ACTIVE_COMPARATOR; Interventions: Other: Late start of NOAC | Intervention Type: OTHER; Name: Early start of NOAC; Assigned to Arm(s): Early start of NOAC | Intervention Type: OTHER; Name: Late start of NOAC; Assigned to Arm(s): Late start of NOAC

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation: Prospective, Multi-centre, Parallel-group, Non-inferiority Trial (RE-LY Study)
Brief Summary: The primary objective of this trial is to demonstrate the efficacy and safety of dabigatran etexilate in patients with non-valvular atrial fibrillation for the prevention of stroke and systemic embolism.


Options:
A: Arm Label: Dabigatran dose 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 2 | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: Dabigatran dose 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 1 | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Dabigatran dose 1; Assigned to Arm(s): Dabigatran dose 1 | Intervention Type: DRUG; Name: Dabigatran dose 2; Assigned to Arm(s): Dabigatran dose 2
B: Arm Label: dabigatran etexilate 150 mg BID; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg twice daily (BID) | Arm Label: matching placebo twice daily (BID); Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo twice daily (BID) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg twice daily (BID); Assigned to Arm(s): dabigatran etexilate 150 mg BID | Intervention Type: DRUG; Name: matching placebo twice daily (BID); Assigned to Arm(s): matching placebo twice daily (BID)
C: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin
D: Arm Label: Dabigatran etexilate (150mg bid); Type: EXPERIMENTAL; Interventions: Drug: Dabigatran etexilate | Arm Label: Warfarin (INR 2.0-3.0); Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin (INR 2.0-3.0) | Intervention Type: DRUG; Name: Dabigatran etexilate; Assigned to Arm(s): Dabigatran etexilate (150mg bid)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation: Prospective, Multi-centre, Parallel-group, Non-inferiority Trial (RE-LY Study)
Brief Summary: The primary objective of this trial is to demonstrate the efficacy and safety of dabigatran etexilate in patients with non-valvular atrial fibrillation for the prevention of stroke and systemic embolism.


Options:
A: Arm Label: Dabigatran dose 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 2 | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: Dabigatran dose 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 1 | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Dabigatran dose 1; Assigned to Arm(s): Dabigatran dose 1 | Intervention Type: DRUG; Name: Dabigatran dose 2; Assigned to Arm(s): Dabigatran dose 2
B: Arm Label: Arm I (apixaban); Type: EXPERIMENTAL; Interventions: Drug: Apixaban, Other: Questionnaire Administration | Arm Label: Arm II (dalteparin); Type: EXPERIMENTAL; Interventions: Drug: Dalteparin, Other: Questionnaire Administration | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Arm I (apixaban) | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): Arm II (dalteparin) | Intervention Type: OTHER; Name: Questionnaire Administration; Assigned to Arm(s): Arm I (apixaban), Arm II (dalteparin)
C: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin
D: Arm Label: Low-molecular-weight heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low-molecular-weight heparin | Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: rivaroxaban | Intervention Type: DRUG; Name: rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Low-molecular-weight heparin; Assigned to Arm(s): Low-molecular-weight heparin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: SimCare: Physician Intervention to Improve Diabetes Care
Brief Summary: This randomized trial will test the hypotheses that (a) a physician opinion leader intervention, (b) a "narrative process trace" physician feedback intervention, or (c) the combined intervention (a + b), are no more effective than (d) usual care in improving the clinical care of adult patients with type 2 diabetes.


Options:
A: Arm Label: Electronic disease management decision support; Type: OTHER; Interventions: Other: Electronic disease management decision support | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Electronic disease management decision support; Assigned to Arm(s): Electronic disease management decision support
B: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: Other: Case Management | Arm Label: Case Management; Type: EXPERIMENTAL; Interventions: Other: Case Management | Intervention Type: OTHER; Name: Case Management; Assigned to Arm(s): Case Management, Usual Care
C: Arm Label: Group A; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Simulated case-based customized learning | Arm Label: Group C; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Simulated case based customized learning + leader feedback | Intervention Type: BEHAVIORAL; Name: Simulated case-based customized learning; Assigned to Arm(s): Group B | Intervention Type: BEHAVIORAL; Name: Simulated case based customized learning + leader feedback; Assigned to Arm(s): Group C
D: Arm Label: Medical group visits; Type: EXPERIMENTAL; Interventions: Other: Diabetes Group Management Visits | Arm Label: Treatment as Usual control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Diabetes Group Management Visits; Assigned to Arm(s): Medical group visits

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: SimCare: Physician Intervention to Improve Diabetes Care
Brief Summary: This randomized trial will test the hypotheses that (a) a physician opinion leader intervention, (b) a "narrative process trace" physician feedback intervention, or (c) the combined intervention (a + b), are no more effective than (d) usual care in improving the clinical care of adult patients with type 2 diabetes.


Options:
A: Arm Label: LTC Osteoporosis Toolkit Only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Educ sessions & LTC Osteoporosis toolkit; Type: ACTIVE_COMPARATOR; Interventions: Other: Educ sessions & LTC Osteoporosis toolkit | Intervention Type: OTHER; Name: Educ sessions & LTC Osteoporosis toolkit; Assigned to Arm(s): Educ sessions & LTC Osteoporosis toolkit
B: Arm Label: Group A; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Simulated case-based customized learning | Arm Label: Group C; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Simulated case based customized learning + leader feedback | Intervention Type: BEHAVIORAL; Name: Simulated case-based customized learning; Assigned to Arm(s): Group B | Intervention Type: BEHAVIORAL; Name: Simulated case based customized learning + leader feedback; Assigned to Arm(s): Group C
C: Arm Label: SSL Implementation Strategy; Type: EXPERIMENTAL; Interventions: Other: SSL Implementation Strategy | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: SSL Implementation Strategy; Assigned to Arm(s): SSL Implementation Strategy
D: Arm Label: MJAP Clinics Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: START | Arm Label: MJAP Clinics Pre-Intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: START; Assigned to Arm(s): MJAP Clinics Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: SimCare: Physician Intervention to Improve Diabetes Care
Brief Summary: This randomized trial will test the hypotheses that (a) a physician opinion leader intervention, (b) a "narrative process trace" physician feedback intervention, or (c) the combined intervention (a + b), are no more effective than (d) usual care in improving the clinical care of adult patients with type 2 diabetes.


Options:
A: Intervention Type: BEHAVIORAL; Name: Opinion Leaders, Academic Detailing, Reminders, and Feedback; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Lifestyle Counselling; Opinion Leader Influence Statements; Assigned to Arm(s): N/A
C: Arm Label: Group A; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Simulated case-based customized learning | Arm Label: Group C; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Simulated case based customized learning + leader feedback | Intervention Type: BEHAVIORAL; Name: Simulated case-based customized learning; Assigned to Arm(s): Group B | Intervention Type: BEHAVIORAL; Name: Simulated case based customized learning + leader feedback; Assigned to Arm(s): Group C
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Patients (education, counseling) and Physicians (reminders,1-page guidelines)., Behavioral: Multifaceted intervention | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: BEHAVIORAL; Name: Patients (education, counseling) and Physicians (reminders,1-page guidelines).; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Multifaceted intervention; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Gemcitabine, Alone or in Combination With Cisplatin, in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumors: A Multicentre, Randomized Phase III Study
Brief Summary: RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known whether gemcitabine is more effective with or without cisplatin in treating cholangiocarcinoma or biliary tract tumors.

PURPOSE: This randomized phase III trial is studying gemcitabine and cisplatin to see how well they work compared to gemcitabine alone in treating patients with unresectable locally advanced or metastatic cholangiocarcinoma or other biliary tract tumors.


Options:
A: Arm Label: GEMOX; Type: ACTIVE_COMPARATOR; Interventions: Drug: gemcitabine, oxaliplatin | Arm Label: E-GEMOX; Type: EXPERIMENTAL; Interventions: Drug: cetuximab, gemcitabine, oxaliplatin | Intervention Type: DRUG; Name: gemcitabine, oxaliplatin; Assigned to Arm(s): GEMOX | Intervention Type: DRUG; Name: cetuximab, gemcitabine, oxaliplatin; Assigned to Arm(s): E-GEMOX
B: Arm Label: Arm NaI-IRI + 5-FU + Leucovorin (Arm A); Type: EXPERIMENTAL; Interventions: Drug: Arm NaI-IRI + 5-FU + Leucovorin (Arm A) | Arm Label: Arm Cisplatin + Gemcitabine (Arm B, standard of care); Type: OTHER; Interventions: Drug: Arm Cisplatin + Gemcitabine (Arm B) | Intervention Type: DRUG; Name: Arm NaI-IRI + 5-FU + Leucovorin (Arm A); Assigned to Arm(s): Arm NaI-IRI + 5-FU + Leucovorin (Arm A) | Intervention Type: DRUG; Name: Arm Cisplatin + Gemcitabine (Arm B); Assigned to Arm(s): Arm Cisplatin + Gemcitabine (Arm B, standard of care)
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: ZD6474, Vandetanib | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: ZD6474, Vandetanib, Drug: Gemcitabine | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: Gemcitabine, Drug: Placebo matching ZD6474 | Intervention Type: DRUG; Name: ZD6474, Vandetanib; Assigned to Arm(s): A | Intervention Type: DRUG; Name: ZD6474, Vandetanib; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): B, C | Intervention Type: DRUG; Name: Placebo matching ZD6474; Assigned to Arm(s): C
D: Arm Label: A - Gemcitabine; Type: EXPERIMENTAL; Interventions: Drug: gemcitabine hydrochloride | Arm Label: B - Gemcitabine and Cisplatin; Type: EXPERIMENTAL; Interventions: Drug: cisplatin, Drug: gemcitabine hydrochloride | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): B - Gemcitabine and Cisplatin | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): A - Gemcitabine, B - Gemcitabine and Cisplatin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prognostic Factors and Risk-Adapted Therapy in Patients With Early Stage Chronic Lymphocytic Leukemia
Brief Summary: RATIONALE: Drugs used in chemotherapy, such as fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Sometimes, the cancer may not need treatment until it progresses. In this case, observation may be sufficient. It is not yet known whether fludarabine is more effective than observation in treating chronic lymphocytic leukemia.

PURPOSE: This randomized phase III trial is studying fludarabine to see how well it works compared to observation only in treating patients with stage 0, stage I, or stage II B-cell chronic lymphocytic leukemia.


Options:
A: Arm Label: Fludarabine; Type: EXPERIMENTAL; Interventions: Drug: Fludarabine | Arm Label: watch & wait; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Fludarabine; Assigned to Arm(s): Fludarabine
B: N/A
C: Arm Label: Fludarabine+Cyclophosphamide+Rituximab (FCR); Type: EXPERIMENTAL; Interventions: Drug: Rituximab, Drug: Cyclophosphamide, Drug: Fludarabine Phosphate | Arm Label: Fludarabine+Cyclophosphamide (FC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Fludarabine Phosphate | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Fludarabine+Cyclophosphamide+Rituximab (FCR) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Fludarabine+Cyclophosphamide (FC), Fludarabine+Cyclophosphamide+Rituximab (FCR) | Intervention Type: DRUG; Name: Fludarabine Phosphate; Assigned to Arm(s): Fludarabine+Cyclophosphamide (FC), Fludarabine+Cyclophosphamide+Rituximab (FCR)
D: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Genetic Counseling for Newly Diagnosed Breast Cancer Patients
Brief Summary: RATIONALE: Genetics education and counseling may help patients make treatment decisions. It is not yet known how genetic counseling or usual care influence patient treatment decisions for breast cancer.

PURPOSE: This randomized clinical trial is studying how well genetic counseling works compared to usual care in helping patients with newly diagnosed ductal carcinoma in situ, stage I, stage II, or stage IIIA breast cancer make treatment decisions.


Options:
A: Arm Label: Telephone genetic counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone Genetic Counseling | Arm Label: In-person genetic counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: In-Person Genetic Counseling | Intervention Type: BEHAVIORAL; Name: Telephone Genetic Counseling; Assigned to Arm(s): Telephone genetic counseling | Intervention Type: BEHAVIORAL; Name: In-Person Genetic Counseling; Assigned to Arm(s): In-person genetic counseling
B: Arm Label: Rapid genetic counseling; Type: EXPERIMENTAL; Interventions: Behavioral: counseling intervention, Other: educational intervention, Procedure: psychosocial assessment and care | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: counseling intervention; Assigned to Arm(s): Rapid genetic counseling | Intervention Type: OTHER; Name: educational intervention; Assigned to Arm(s): Rapid genetic counseling | Intervention Type: PROCEDURE; Name: psychosocial assessment and care; Assigned to Arm(s): Rapid genetic counseling
C: Arm Label: Contraceptive Decision Support Tool; Type: EXPERIMENTAL; Interventions: Behavioral: Contraceptive Decision Support Tool | Arm Label: Usual Care (Control); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Contraceptive Decision Support Tool; Assigned to Arm(s): Contraceptive Decision Support Tool
D: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Education Counseling Session for PSA Screening | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: General Health Counseling Coaching | Intervention Type: BEHAVIORAL; Name: Education Counseling Session for PSA Screening; Assigned to Arm(s): Intervention Group | Intervention Type: BEHAVIORAL; Name: General Health Counseling Coaching; Assigned to Arm(s): Control Group

Answer: B